Shots:

• The agreement is focus on developing and commercializing ARO-HBV that can improve QoL for chronic hepatitis B It includes drug candidate ARO-HBV along with option to license three additional treatments for Hepatitis B
• Arrowhead to get an upfront $175M with $1.6B milestone payments for ARO-HBV. $1.9B in option and milestone payments for the three additional treatments of Hepatitis B. Janssen will invest $75M in its Arrowhead’s shares at a price of $23/share
• Janssen will take on Arrowhead’s ARO-HBV drug candidate currently evaluated in P-I/II- will also initiate the P-IIb trial for ARO-HBV and up to three RNAi therapeutics. Janssen will also jointly develop RNAi therapeutics using Arrowhead’s Targeted RNAi Molecule (TRiM) platform. The transaction is expected to close in Q4’18

Ref: Janssen | Image: Janssen